Cart
sales@molnova.com
SD 169
CAS No. 1670-87-7
SD 169( —— )
Catalog No. M20928 CAS No. 1670-87-7
SD 169 is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 50MG | 32 | In Stock |
|
| 100MG | 47 | In Stock |
|
| 200MG | 70 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSD 169
-
NoteResearch use only, not for human use.
-
Brief DescriptionSD 169 is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
-
DescriptionSD 169 is a selective and ATP competitive the MAP kinases p38α and p38β inhibitor.
-
In VitroSD-169 significantly reduces p38 and HSP60 expression in T cells of the pancreatic beta islets.SD-169 demonstrates 38-fold potency against p38α MAP kinase (IC50=3.2 nM) than p38β MAP kinase (IC50=122 nM).
-
In Vivo——
-
Synonyms——
-
PathwayMAPK/ERK Signaling
-
Targetp38 MAPK
-
Recptorp38
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1670-87-7
-
Formula Weight160.17
-
Molecular FormulaC9H8N2O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (624.30 mM)
-
SMILESNC(=O)c1ccc2[nH]ccc2c1
-
Chemical Name1H-Indole-5-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Myers R R Sekiguchi Y Kikuchi S et al. Inhibition of p38 MAP kinase activity enhances axonal regeneration[J]. Experimental Neurology 2003 184(2):0-614.
molnova catalog
related products
-
PAF (C16)
PAF (C16) is a potent MAPK and MEK/ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.
-
Losmapimod
Losmapimod (GSK-AHAB, GW856553X, SB856553)?is a selective, potent, orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.
-
SC-806
A potent, orally active p38 MAPK inhibitor with IC50 of 50 nM.
